TABLE 1B.
Patient Characteristics by de novo class II DSA status.
| Factors | De novo DR/DQ | De novo DR/DQ | P-value |
|---|---|---|---|
| DSA (+) (n = 100) | DSA (−) (n = 591) | ||
| Observation period | 80.8 +/– 28.7 | 78.3 +/– 27.5 | |
| Recipient age | 44.7 +/– 17.4 | 46.6 +/– 15.6 | |
| Recipient M/F | 73/27 | 378/213 | 0.0886 |
| Donor age | 56.9 +/– 11.1 | 58.0 +/– 10.1 | |
| Donor M/F | 29/71 | 213/378 | |
| Parent/sibling/spouse/others | 45/8/38/9 | 244/53/276/18 | |
| CSA/TAC | 60/40 | 292/299 | 0.0522 |
| MMF/MZR/EVR | 77/8/15 | 501/30/60 | |
| RIT/SPX/NONE | 20/2/78 | 154/8/429 | |
| HLA-A+B MM | 2.2 +/– 0.9 | 2.2 +/– 1.0 | |
| HLA-DRB1 MM | 1.3 +/– 0.5 | 1.2 +/– 0.6 | |
| HLA-DQB1 MM | 1.3 +/– 0.5 | 1.1 +/– 0.7 | |
| HLA-DRB1+DQB1 MM | 2.6 +/– 0.9 | 2.3 +/– 1.3 | |
| HLA-A+B+DRB1+DQB1 MM | 4.8 +/– 1.6 | 4.5 +/– 2.0 | |
| ABO-I/ABO-Id/C | 24/76 | 213/378 | 0.0223 |
| Eplet MM (A+B) | 11.0 +/– 6.8 | 11.2 +/– 6.4 | |
| Eplet MM (DRB) | 15.0 +/– 7.9 | 10.7 +/– 8.8 | <0.0001 |
| Eplet MM (DQB) | 11.0 +/– 5.7 | 7.9 +/– 6.5 | <0.0001 |
| Eplet MM (DRB+DQB) | 25.9 +/– 10.9 | 18.6 +/– 13.3 | <0.0001 |
| PIRCHE score | 265.5 +/– 139.1 | 205.3 +/– 137.8 | <0.0001 |
| Acute TCMR | 20 (20.0%) | 36 (6.1%) | <0.0001 |
| CMV infection | 26 (26.0%) | 172 (29.1%) |
DSA, donor specific antibody; CSA, cyclosporine; TAC, tacrolimus; MMF, mycophenolate mofetil; MZR, mizoribine; EVR, everolimus; RIT, rituximab; SPX, splenectomy; MM, mismatch; ABO-I, ABO-incompatible transplantation; ABO-Id/C, ABO-identical/compatible transplantation; TCMR, T cell mediated rejection.